Content Type: Article

  • VBC Symposium 2023 | Find Your Niche: Value-Based Models for Clinical Specialties

    VBC Symposium 2023 | Find Your Niche: Value-Based Models for Clinical Specialties

    ARTICLE

    VBC Symposium 2023 | Find Your Niche: Value-Based Models for Clinical Specialties

    May 8, 2023

    Read time: 3 min

    Key takeaways
    Overview

    During this session, Partner Jeremy Earl moderated a panel that collected insights on how specialists can participate in value-based care and the unique challenges specialists face in maximizing value-based care opportunities.

    Session panelists included:

    • Marissa Brittenham, Executive Vice President and Chief Strategy Officer, Surgery Partners
    • David Dempsey, Chief Operating Officer, Heartbeat Health
    • David Eagleton, Senior Vice President, Oncology Care Partners
    • Jeremy Earl, Partner, McDermott Will & Emery (Moderator)
    • Josh Goldenberg, Group Vice President of Payor Partnerships, DaVita Inc.
    In depth

    Top takeaways included:

    1. While some specialists are comfortable in the value-based care world, others have been slow to engage with and adopt value-based care initiatives. Convincing providers who have been paid on a fee-for-service basis their entire career to shift and take on risk can be challenging. These shifts can begin slowly, for example, by offering initial quality bonuses and then building up to longer-term strategies. However, the transition often involves a shift in mindset and can be challenging to accomplish at an organizational level.
    2. Specialists may only have insight into a small portion of a patient’s life, so it can be hard to engage in the patient’s full care journey when specialists are not at the center of care. However, where specialists can provide a service for a fraction of the cost—for example, through site-of-care shifts—specialists can still have a large impact on costs and outcomes.
    3. Different specialties are at different points in the value-based care transformation. The panelists representing ASCs and oncology, cardiology and dialysis providers, for example, generally agreed that kidney-care providers are furthest along in the value-based care evolution, although each of their respective specialties is making strides toward value-based care adoption.
    4. Payers are increasingly becoming receptive to risk-based contracts with specialists. As the growth in specialty-care spend has increased, so too has payer engagement and their willingness to contract. The decision as to who takes on the risk and how the risk is contracted for (e.g., directly or through an MSO) can vary from one specialty to the next. Specialists may be open to different risk arrangements if such arrangements allow them to gain lives in new markets.
    5. Specialists remain focused on high-impact activities that have the potential to drive patient engagement. These can include patient-facing apps that help to track and monitor patients’ symptoms, as well as medication reconciliation, virtual care delivery, healthcare navigators and collaborations with start-ups to identify the appropriate interventions for the right patients.
    Authors

    Jeremy Earl

    Partner

    Washington, DC

    More insights

  • VBC Symposium 2023 | Innovations in Value-Based Care for Complex Populations

    VBC Symposium 2023 | Innovations in Value-Based Care for Complex Populations

    ARTICLE

    VBC Symposium 2023 | Innovations in Value-Based Care for Complex Populations

    May 8, 2023

    Read time: 5 min

    Key takeaways
    Overview

    During this session, Partner Jeremy Earl moderated a panel that discussed how value-based care models are delivering care to individuals with complex conditions and those with significant healthcare and social needs. The panel also provided perspectives from executives at companies that are revolutionizing the delivery of care to high-needs populations and demonstrating how doing good can also be a successful business model.

    Session panelists included:

    • Christopher Aguwa, Executive Vice President & Head of Growth and Business Development, Cityblock
    • Benjamin Kornitzer, MD, Chief Medical Officer, agilon health
    • Hank Watson, Chief Development Officer, American Health Partners
    • Lea Tompsett, Head of Provider Enablement, Waymark
    In depth

    Top takeaways included:

    1. Focus on Empowering and Elevating Providers. The companies that are successfully delivering care to complex populations are those that are focused on empowering and elevating providers to fill in gaps in care; such entities also succeed on cost and outcome goals as a result. These companies primarily focus on primary care providers (PCPs), nursing homes and related front-line providers. The panelists who focus their efforts on primary care do so in the belief that primary care can have the greatest impact on outcomes. Traditionally, primary care has been delivered within the four walls of a PCP’s office, with fee-for-service (FFS) reimbursement. Companies take different approaches to moving outside of this traditional model: Some focus on extending services outside of the PCP’s office to fill in gaps in care, such as deploying nurses to the home. Others seek to enable PCPs with data and resources to identify patients with complex needs and to better advocate and care for those patients once identified. Other companies seek to take tasks off PCP’s plates, enabling them to spend more time on patient interactions that drive better outcomes.
    2. Patient Engagement Is Critical to Success. To be successful in value-based care models with downside risk, companies must be excellent at patient engagement. Accordingly, when working with complex populations, the panelists discussed how there is significant focus on engaging patients, building a person-to-person connection, understanding patients’ needs, developing trust and providing patients with care where they want to seek care. Many successful companies utilize nonclinical personnel in this process, including community health workers and community health partners. The importance of patient engagement is also why many successful companies organize their models around PCPs, with the panelists discussing how patient engagement and, in turn, positive outcomes increase when a trusted PCP is involved.
    3. Addressing Social Deteriments of Health in Value-Based Care Models. For individuals with complex conditions, social determinents of health (SDOH) also impact outcomes and costs. We have seen a greater willingness in Medicare and Medicaid to think about what should be funded to achieve better outcomes. The panelists thought this was an important policy shift, with one noting that risk-bearing models allow companies to reinvest surpluses back into the community and fund resources that impact SDOH, such as transportation, food and air conditioning.
    4. Differences in Full-Risk Value-Based Care Arrangements in Medicaid versus Medicare. The panel also touched on the differences between Medicare and Medicaid and how companies think about full risk in these programs. In Medicare, there are two levers that companies can pull to be successful: the revenue lever (e.g., more accurate and more complete coding) and the cost lever. However, in most Medicaid programs, there is only the cost lever since risk-adjusted premiums are not a feature in most Medicaid managed care programs. Moreover, the difference in how medical loss ratio (MLR) is defined at the state level versus the federal level can make value-based contracting difficult, as many state Medicaid programs do not include quality initiatives in their MLR definition. As a result, value-based care in Medicare Advantage (MA) is well established, and parties are well versed on value-based care. This is not necessarily the case in Medicaid, which has increased levels of complexity because of state-by-state differences, lower funding levels and, in many cases, less knowledge about value-based care. There is significantly fewer value-based care deals in the Medicaid space today as a result. One panelist noted that value-based care arrangements in Medicaid remain at the beginning stages, which presents challenges but also presents room for innovation. Another panelist observed that because there are very slim margins in Medicaid compared to MA, successful companies in the Medicaid space must be very strong on operational execution.
    Authors

    Jeremy Earl

    Partner

    Washington, DC

    More insights

  • VBC Symposium 2023 | Washington Update

    VBC Symposium 2023 | Washington Update

    ARTICLE

    VBC Symposium 2023 | Washington Update

    May 8, 2023

    Read time: 3 min

    Key takeaways
    Overview

    During this session, Mara McDermott, former Vice President, McDermott+Consulting, moderated a panel that discussed the current political and policymaking environment on Capitol Hill and what to watch for in 2023.

    Session panelists included:

    • Dr. Lauren Lyles-Stolz, Senior Director, Reimbursement, Innovation and Advocacy, National Association of Chain Drug Stores (NACDS)
    • Mara McDermott, former Vice President, McDermott+Consulting (Moderator)
    • Aisha Pittman, Senior Vice President, Government Affairs, National Association of ACOs (NAACOS)
    • Soumi Saha, Senior Vice President of Government Affairs, Premier Inc.
    In depth

    Top takeaways included:

    1. Legislative and regulatory stakeholders have created a number of opportunities to engage in value-based care, including through the creation of the Center for Medicare and Medicaid Innovation (CMMI) and the Medicare Shared Savings Progam (MSSP). However, many of these initiatives have been—and continue to be—influenced by political and agency decision making. Therefore, educating members of Congress on why value is important remains a top priority.
    2. Stakeholders are advocating for greater predictability and alignment across value-based initiatives. There are many competing interests in the system today, with Centers for Medicare & Medicaid Services (CMS) initiatives trending in different directions (e.g., Medicare Advantage versus MSSP). There are questions regarding how pharmacy services can better integrate into value-based care, how to engage specialists, how to sustain Medicare Advantage and more. Creating a pathway for all of these initiatives and stakeholders to coexist will be challenging, but could lead to greater value.
    3. Better data is needed across programs. Faster, higher-quality data would allow CMS to more quickly cost-correct during the implementation of its value-based models and other initiatives. More data—ranging from program benchmarks to how health equity is calculated and accounted for—is needed to support and address ongoing technical challenges.
    4. As Congress looks at reimbursement as a whole, incentives will be critical to encouraging the adoption of value-based care. How legislative and regulatory stakeholders design new initiatives and revise existing models will influence providers’ willingness to participate, as providers and other stakeholders continue to juggle competing priorities.
    Authors
    More insights

  • VBC Symposium 2023 | Weathering The Storm: A Data-Driven Perspective on Value-Based Care, by Bain & Company

    VBC Symposium 2023 | Weathering The Storm: A Data-Driven Perspective on Value-Based Care, by Bain & Company

    ARTICLE

    VBC Symposium 2023 | Weathering The Storm: A Data-Driven Perspective on Value-Based Care, by Bain & Company

    May 8, 2023

    Read time: 7 min

    Key takeaways
    Overview

    In this session, Erin Ney and Jason Slocum of Bain & Company provided data-driven insights on the current state of the value-based care industry. The session provided a look at the factors influencing provider adoption of risk-based adoption, the most promising investment opportunities in value-based care, and how likely the value-based care industry is to weather an economic downturn.

    In depth

    Top takeaways included:

    1. Nearly 60% of healthcare payments in 2021 had at least some element tied to quality and value. However, the majority of these payments were upside risk, with less than 20% incorporating down-side risk. At the same time, nearly 40% of healthcare payments are not in value-based care models.
    2. Around 80% of physicians surveyed are interested in participating in value-based care arrangements. However, that interest significantly decreases as the level of risk to the provider increases.
    3. Providers continue to face financial, operational and administrative hurdles to adopting value-based care. Providers’ sense of preparedness across the financial, operational and administrative dimensions have decreased since 2017, with providers surveyed feeling less equipped to adopt and succeed in value-based care models.
    4. To make providers more inclined to adopt value-based care, providers stated that they needed more sufficient financial resources, more effective coding and billing processes, and investments in additional staff to manage data, reporting and outreach. Similarly, providers reported they needed three key groups of enablers in order to transition from fee-for-service to risk-based models: (1) clinical care model enablers, (2) data and technology enablers, and (3) payor contracting enablers.
    5. There are a variety of investment opportunities in the value-based care space, including payor-centric options, provider-centric options (traditionally in primary care, but there has been recent growth in single- and multi-specialty models), and enablers in the value-based care ecosystem, e.g., enabling tools and technologies such as healthcare IT, platforms and services.
    6. Over the last five years, the volume and value of deals related to value-based care increased. While there was a decline in deals related to value-based care in 2021–2022, the momentum around value-based care investments remains strong. This momentum may be blunted in the short term by current macroeconomic forces, as value-based care adoption requires capital and risk; however, the long-term investment outlook remains strong.

    A Deeper Dive

    Where are we today and where have we been?

    As of 2021, nearly 60% of healthcare payments had at least some element tied to quality or value. However, the majority of these payments were upside-only models, with less than 20% incorporating down-side risk (with capitated models under 8% of spending). However, in the last five years, risk-based models have continued to gain traction. These are full-risk models, with full and partial capitation, as well as shared-risk models, with upside and downside risk. As providers have dipped their toes in the pool of value-based care, have gotten used to taking risk with pay-for-performance, and have started to build capabilities for risk-based models, we see movement over the last five years to full-risk models. While adoption of risk-based models has grown, nearly 40% of healthcare payments are not in value-based care models. Thus, a key question is what it will take to move the needle for this group to adopt value-based care.

    While the adoption of risk-based models has grown across all lines of business, the growth has been greatest in Medicare Advantage (MA). There have also been a number of innovative care models in primary care around fully capitated care delivery. There are advantages when providers are taking care of a narrow patient popution that allows the provider to hone capabilities in care models, care delivery, data analytics and payor contracting, all of which allow these providers to succeed in value-based care.

    Where are we headed?

    Looking forward, more than 80% of payers are confident that the prevalence of shared-risk and full-risk models will continue to increase. This is on the tailwinds of rising costs of acute care, increases in chronic conditions, regulatory iniatives, provider consolidation and the profileration of data analytics. At the same time, around 80% of physicians surveyed in Bain’s recent “Frontline of Healthcare” survey stated that they are interested in participating in value-based care arrangements. However, that interest declines as the level of risk to the provider increases. For example, while 50% of physicians surveyed stated they were interested in pay-for-performance or quality payment initiatives, only 13% were interested in full-capitation models.

    Provider adoption of value-based care is not monolithic. The models that specialities adopt and the speed of adoption will vary. Factors influencing this adoption include whether there is a clear standard of care to measure against; whether there is an ability to manage the full cost of care or steer care to other specialties; whether there are clearly defined conditions with clear start and end dates; whether there is a potential for cost reduction in prescriptions; and whether there is a potential for cost reduction through site-of-care shifts or technology. Whether these factors are addressable range across specialities.

    What will it take to increase adoption in the future?

    According to Bain’s “Frontline of Healthcare” survey, providers recognize that value-based care has positive impacts on quality of care, can be more efficient for patient care and presents an increased financial upside. However, providers have concerns about complexity and financial risk, as well as questions as to whether value-based care models are actually succeeding today. Bain research shows that physicians continue to face financial, operational and administrative hurdles to adopting value-based care. Providers’ sense of preparedness to adopt value-based care across the financial, operational and administrative dimensions have actually decreased since 2017, with providers feeling considerably less equipped to adopt value-based care models.

    Two possible explanations for this decreased sense of preparedness include the increased capabilities required to succeed in greater-risk models compared to upside-only models, and changes in care models, resources and goals following the COVID-19 pandemic.

    The top three items providers cited as making them more interested or willing to adopt value-based care models were: (1) more sufficient financial resources, (2) more effective coding and billing processes, and (3) investments in additional staff to manage reporting and outreach requirements. Similarly, physicians reported that they needed three key groups of enablers in order to transition from fee-for-service models to risk-based models: (1) clinical care model enablers, (2) data and technology enablers, and (3) payor contracting enablers.

    What are the current market dynamics and the path forward?

    Over the last five years, the volume and value of deals related to value-based care increased. While there was a decline in deals related to value-based care in 2021–2022, the momentum around value-based care investments remains strong. There are a ranger of potential ways to play in the value-based care space, inclyding payor-centric options, provider-centric options and options focused around enablers in the value-based care ecosystem, including healthcare IT, services and platforms that help providers take on risk. While most investment has traditionally flowed into risk-bearing primary care provider models, we are starting to see more interest in risk-bearing single- and multi-speciality models. We are also seeing funds dedicated to value-based care, as well as funds putting together pools to go after earlier stage value-based care companies.

    We are currently in a more difficult economic cyle. Value-based care adoption requires capital and has risk. Forces around inflation, labor inflation and a general economic downturn could slow provider adoption of risk-based models in the short term if providers cannot afford the required investments to succeed in these models. These macroeconomic forces may also slow private investment in the short term. However, there is a long-term investment theme for value-based care.

    Authors
    More insights

  • PPM ASC Symposium 2023 | Washington Outlook: Evolving Federal Policy Impacting Reimbursement, Operations and Deal Strategies

    PPM ASC Symposium 2023 | Washington Outlook: Evolving Federal Policy Impacting Reimbursement, Operations and Deal Strategies

    ARTICLE

    PPM ASC Symposium 2023 | Washington Outlook: Evolving Federal Policy Impacting Reimbursement, Operations and Deal Strategies

    May 8, 2023

    Read time: 4 min

    Key takeaways
    Overview

    In this session, panelists discussed the political shifts in Washington that are impacting healthcare reimbursement, operations, and deal strategies, including Centers for Medicare & Medicaid Services (CMS) policies on reimbursement, recent activity regarding non-competes and consolidation, and the end of the COVID-19 public health emergency (PHE).

    Session panelists included:

    • Brian Fortune, President, Farragut Square Group
    • Deborah Godes, Vice President, McDermott+Consulting
    • Katharine O’Connor, Partner, McDermott Will & Emery
    • William Prentice, Chief Executive Officer, Ambulatory Surgery Center Association
    • Eric Zimmerman, Principal, McDermott+Consulting, and Partner, McDermott Will & Emery (Moderator)
    In depth

    Top takeaways included:

    • Eight years after the passage of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), CMS continues to make adjustments to calibrate physician reimbursement. As they do so, budget neutrality requirements continue to hamper progress. Providers may have to look to the US Congress to get involved and implement an inflation adjustment factor to the fee schedule.
    • Ambulatory Surgery Centers (ASCs) may face challenges in obtaining favorable reimbursement as they enter the fifth year of a pilot program in which they have been receiving the same inflation adjustments as hospitals. At the end of the pilot program, it is unclear whether ASC reimbursement will continue to receive the hospital market basket adjustments or go back to Consumer Price Index (CPI) adjustments, which have historically been less favorable than hospital inflation adjustments.
    • Site neutrality continues to be a hot topic as CMS and Congress looks for ways to minimize incentives to refer patients to one setting over another (e.g., hospitals versus ASCs versus physician offices). From a deal standpoint, if part of the attractiveness of a target physician practice is that it is getting paid 30% to 40% higher than a hospital outpatient setting, buyers should be careful, as CMS is always looking for ways to close that gap, typically manifesting in the form of lower physician clinic rates.
    • While the Biden administration began with significant rhetoric addressing healthcare mergers and consolidations, challenges to consolidation have not actually increased in the form of merger challenges. Legislation addressing consolidation has also slowed down in the latter half of the administration.
    • Even though the Federal Trade Commission’s (FTC) proposed ban on non-compete clauses is not yet in effect and may be modified before it is issued as a final rule, the FTC has already begun to crack down on non-competes in the healthcare industry. If a provider is submitting documents to the FTC for a merger or an investigation, the FTC will most likely be reviewing the provider’s non-competition provisions during that process.
    • During the past three years, the PHE has led providers to make significant adjustments in their operations to take advantage of hundreds of statutory and regulatory flexibilities. As the PHE comes to an end on May 11, 2023, providers will need to make adjustments to go back to pre-2020 operations, which could be challenging in some instances. The administration has stated that they intend to use the PHE flexibilities to learn lessons and solicit feedback on which flexibilities should remain in place, but it is unlikely that CMS will make any new announcements between now and May 11. Outside of the federal policy arena, some states may continue their flexibilities, and some commercial plans that took inspiration from CMS may also continue their flexibilities after May 11.
    Authors

    Eric Zimmerman

    Partner

    Washington, DC

    More insights

  • PPM ASC Symposium 2023 | State of the PPM Industry: Perspectives from Top CEOs

    PPM ASC Symposium 2023 | State of the PPM Industry: Perspectives from Top CEOs

    ARTICLE

    PPM ASC Symposium 2023 | State of the PPM Industry: Perspectives from Top CEOs

    May 8, 2023

    Read time: 5 min

    Key takeaways
    Overview

    During this session, Partner Jerry Sokol moderated a panel in which top CEOs shared their insights on capitalizing on opportunities and overcoming obstacles in the current environment. They discussed the transition to value-based care, the No Surprises Act (NSA), physician alignment and the future of the physician practice management (PPM) deal landscape, among other topics.

    Session panelists included:

    • Bob LaGalia, President & CEO, Unified Women’s Healthcare
    • James Swift, MD, CEO, Pediatrix Medical Group, Inc.
    • Corina Tracy, CEO, U.S. Urology Partners
    • James Weber, MD, CEO, GI Alliance
    • Rich Whitney, Founder, Chairman & CEO, Radiology Partners
    In depth

    Top takeaways included:

    • Value-Based Care.
      • At this time, industry players are focused on building capabilities to ensure they are ready for the transition to value-based care. Changes to payment programs may take a long time, but using this time to prepare and focus on adding value can help with long-term success.
      • One of the biggest challenges platforms face when adopting value-based care models is physician engagement. Strategies for enhancing engagement include aligning economic incentives (while protecting physicians from risk) and investing in the right technology infrastructure and tools to support value-based care delivery.
      • Data aggregation and actuarial analysis are critical to success in a value-based environment. Providers and platforms need to understand the historical costs, treatment patterns, and other characteristics of their patient population and carefully assess the financial implications of a value-based care arrangement before making the jump.
      • Payors are not always ready for value-based care, even when platforms and providers initiate outreach. Payor readiness may depend on the provider’s specialty area. For example, payors may have a more difficult time creating programs for specialties that cover lifelong chronic diseases. This presents an opportunity for providers to work with payors to design new value-based programs that facilitate the right incentives.
    • Challenges for Hospital-Based PPMs.
      • The implementation of the NSA—particularly the independent dispute resolution (IDR) process—has been an enormous challenge. PPMs are beginning to see plans and issuers move away from the IDR process and toward negotiated resolutions and in-network agreements. In the meantime, the IDR process and other provisions of the NSA continue to cause significant industry disruption.
    • Physician Alignment.
      • Proper physician alignment is paramount to the success of any PPM company. Successful PPM companies (1) build credibility and trust with providers; (2) develop the proper incentives for physicians to capture growth through productivity, including a good compensation program and equity ownership in the parent company so that successes and challenges are shared; and (3) prioritize transparency, including shared data and physician involvement in governance and the decision-making process.
      • When incentives align, physicians can contribute in significant ways to the success of their enterprises, including by recruiting physicians, identifying acquisition targets and working collaboratively to solve problems as they arise. Executive teams and investors can be significant resources for allowing physicians to succeed in this ever-changing environment that is increasingly difficult for independent practices to navigate. However, for the industry to succeed in navigating changes and challenges, physicians need to be at the center of decision-making and innovation.
    • Transactional Activity: Build vs. Buy.
      • While transactional activity will continue in 2022 and beyond, PPMs are taking a more disciplined approach to ensure that acquisition targets will fill gaps or otherwise add value and be the right cultural fit to join their enterprises.
      • PPMs who have achieved scale are also shifting their primary focus to organic growth by expanding through de novo practices, provider hiring and smaller tuck-in acquisitions.
    • Long-Term Future of the PPM Industry.
      • PPM is here to stay. As the industry continues to evolve and market pressures change, there is a significant advantage to having the scale provided by PPMs, which allows providers to improve care, manage the cost of regulatory burdens, and drive efficiencies.
      • PPM leaders anticipate that an additional wave of consolidation is coming. Large platforms will need to lead the way through investment in technology and appropriate skill set balances to help the industry adapt to the changing dynamics, including the scarcity of physicians.
      • Succeeding in the future will require an increased focus on physicians and other clinicians. Certain PPMs are moving in on advanced practice providers and working to have sufficient physicians in the pipeline.
    Authors

    Jerry J. Sokol

    Partner

    Miami

    More insights

  • PPM ASC Symposium 2023 | Trends in Value-Based Care Models

    PPM ASC Symposium 2023 | Trends in Value-Based Care Models

    ARTICLE

    PPM ASC Symposium 2023 | Trends in Value-Based Care Models

    May 8, 2023

    Read time: 3 min

    Key takeaways
    Overview

    In this session, McDermott Will & Emery Partner Matthew Perreault moderated a panel that collected insights on how the value-based care market has shifted, how investors and other stakeholders can partner on value-based care initiatives, and the different challenges that primary and specialty care providers are facing today.

    Session panelists included:

    • Rick Goddard, Vice President, Commercialization & Strategy, Lumeris
    • Matthew Perreault, Partner, McDermott Will & Emery
    • Scott Rosen, Partner, Transformation Capital
    • Robin Shah, Founder and Chief Executive Officer, Thyme Care
    • Kyle Wailes, Chief Executive Officer, Wellvana
    In depth

    Top takeaways included:

    • Investment and interest in value-based care has never been stronger. Historically, many stakeholders have thought about value-based care defensively. Today, there are opportunities to engage in value-based care more offensively. There are different approaches to take in entering the market, and more partners and intermediaries to collaborate with than ever before.
    • Value-based care is not a one-size-fits-all model. Stakeholders should be deliberate in their approach and consider the right geographies, lines of business, and partners for growing their businesses. This could involve acquiring a primary care practice directly, partnering with a payor to identify a market for growth, building high-performing and/or affiliate networks, and more.
    • Those looking to invest in value-based care should consider factors such as the following: whether the model produces better clinical outcomes and cost savings; how to engage patients; whether the model is scalable from one geography to the next; how to contract with payors who typically have better data; what tools will generate value quickly; and whether ancillary opportunities exist.
    • Driving value in the long term will depend on physician engagement. As the Medicare program adopts new policies and models, other lines of insurance are likely to follow, and it is important to bring physicians—who are at the center of care—along. The focus in the market has shifted to achieving profitability today and successful models will be those that can differentiate their abilities and demonstrate high-impact value where others cannot.
    Authors
    More insights

  • SEC Requires New Disclosures in Periodic Reports on Share Repurchases

    SEC Requires New Disclosures in Periodic Reports on Share Repurchases

    ARTICLE / CLIENT ALERT

    SEC Requires New Disclosures in Periodic Reports on Share Repurchases

    May 8, 2023

    Read time: 7 min

    Key takeaways
    Overview

    On May 3, 2023, the US Securities and Exchange Commission (SEC) adopted amendments to the share repurchase disclosure rules that require the disclosure of daily share repurchase activity on a quarterly basis by domestic issuers and foreign private issuers and on a semi-annual basis by registered closed-end management investment companies (Listed Closed-End Funds). Domestic issuers are required to comply with these amendments beginning with their first periodic report that covers the first full fiscal quarter commencing on or after October 1, 2023. Foreign private issuers are required to file a new Form F-SR on a quarterly basis to comply with the amendments beginning with their first full fiscal quarter that commences on or after April 1, 2024, and must provide additional disclosures in their first Form 20-F following their first Form F-SR filing. Listed Closed-End Funds must comply beginning with their Form N-CSRs that cover the first six-month period that starts on or after January 1, 2024.

    In depth

    BACKGROUND

    Prior to the adoption of these amendments, Item 703 of Regulation S-K required disclosure of share repurchase transactions consummated by a domestic issuer in its quarterly reports on Form 10-Q and annual report on Form 10-K, repurchases by a foreign private issuer to be disclosed annually in its Form 20-F and semi-annual disclosure of repurchases for Listed Closed-End Funds. The previously required disclosures included (1) the total number of shares repurchased as measured on a monthly basis and the nature of the purchases (e.g., whether the repurchases were made in open-market transactions, tender offers, in satisfaction of the issuer’s obligations upon exercise of outstanding put options issued by the issuer or other transactions), (2) the average price paid per share, (3) the total number of shares purchased as part of publicly announced plans or programs, and (4) the maximum number of shares that may be purchased under the plans or programs following the reported purchases. In December 2021, the SEC proposed amendments to Item 703 to address the gaps in disclosure rules on share repurchases and insider trades that allow corporate insiders “to unfairly exploit information asymmetries between issuers and investors.” These proposed amendments would have required issuers to report share repurchases and related information on Form SR one business day after execution of the repurchase. Following comments regarding the burdens of these proposed amendments, the SEC adopted a modified version of enhanced disclosure requirements for share repurchases (as described below).

    NEW DISCLOSURE RULES

    The new disclosure rules will require domestic issuers to make these disclosures on an exhibit to their quarterly reports on Form 10-Q and annual report on Form 10-K for the period covered by the report (or the fourth fiscal quarter in the case of a Form 10-K). Foreign private issuers are required to make the new disclosures within 45 days following the end of their fiscal quarter on a new Form F-SR. Issuers will no longer need to disclose monthly repurchase data in periodic reports. Listed Closed-End Funds are required to make the new disclosures in their annual and semi-annual reports on Form N-CSR. All of these disclosures must be data tagged.

    The amendments set forth the following changes and additional disclosure requirements for an issuer:

    1. Daily Repurchase Data. Issuers will be required to include disclosure of their repurchase activity aggregated on a daily basis in a tabular format that specifies (1) the class of shares repurchased, (2) the average price paid per share, (3) the total number of shares repurchased and the total number of shares repurchased through a plan that was publicly announced by the issuer, (4) the aggregate maximum number of shares that may yet be purchased under a publicly announced plan, (5) the total number of shares repurchased on the open market, and (6) the total number of shares repurchased that are intended to qualify for the Rule 10b-18 safe harbor for issuer repurchases and the number of shares repurchased by way of a plan intended to satisfy certain conditions of Rule 10b5-1(c). Domestic issuers are required to disclose this information for the period covered by their reports (or the fourth fiscal quarter in the case of a Form 10-K). Foreign private issuers are required to disclose this information on new Form F-SR on a quarterly basis. Listed-Closed End Funds must make these disclosures on a semi-annual basis for the period covered by their Form N-CSR.
    2. Enhanced Narrative Disclosures. Narrative disclosures regarding share repurchases will be required to address (1) the objectives and rationales for the issuer’s repurchases and the processes and criteria used to determine the amount of such repurchases, and (2) the issuer’s policies and procedures relating to purchases and sales of the issuer’s securities by its officers and directors during the period a repurchase program is active.
    3. New Item 408(d) of Regulation S-K. A domestic issuer will be required to disclose the adoption and termination of any Rule 10b5-1 trading agreement that it entered into during the period covered by a periodic report (or the fourth fiscal quarter in the case of a Form 10-K).
    4. Sales by Insiders Close to the Announcement of a Repurchase Plan. Issuers must also disclose through a checkbox whether any Section 16 officers and directors (or directors and members of senior management required to be identified pursuant to Item 1 of Form 20-F in the case of foreign private issuers) purchased or sold shares that are the subject of an issuer share repurchase plan or program within four business days before or after the announcement of that particular plan or program.
    5. Quarterly Reporting for Foreign Private Issuers. These amendments create a new quarterly reporting obligation for foreign private issuers. A foreign private issuer who does not file periodic reports on Form 10-Q and Form 10-K must file the new Form F-SR to disclose the required share repurchase information within 45 days after the end of a fiscal quarter. Foreign private issuers must also include narrative disclosures in their Form 20-F based on their Form F-SR filings during the period covered by Form 20-F regarding (1) the objectives or rationales for each repurchase plan or program and the criteria used to determine the amount of repurchases, (2) the number of shares purchased through a publicly announced plan or program and the nature of the transaction, (3) the date announced, dollar amount approved, expiration date and expiration or termination of any publicly announced repurchase plan or program within the period covered by Form 20-F and (4) the policies and procedures relating to the purchase and sale of the issuer’s securities by directors and members of senior management.

    McDERMOTT INSIGHT

    These new disclosure requirements reflect the SEC’s increased scrutiny of potential manipulative practices of issuers and insiders in connection with share repurchase programs. In preparation for compliance with the new disclosure rules, issuers should (1) evaluate their policies regarding trades made by directors and officers while a repurchase program is in effect and (2) document the rationale for their repurchases and the criteria and process employed to determine the amount of repurchases.

    Authors

    Diana Douglas

    Partner

    Silicon Valley

    Mark J. Mihanovic

    Partner

    Silicon Valley, Los Angeles

    Eric Orsic

    Partner

    Chicago

    Heidi J. Steele

    Partner

    Chicago

    Peter T. Healy

    Partner

    San Francisco

    More insights

  • Caution for Nonprofits Doing Business with Insiders: IRS Revokes 501(c)(3) Status Based on Management Company Relationship

    Caution for Nonprofits Doing Business with Insiders: IRS Revokes 501(c)(3) Status Based on Management Company Relationship

    ARTICLE / CLIENT ALERT

    Caution for Nonprofits Doing Business with Insiders: IRS Revokes 501(c)(3) Status Based on Management Company Relationship

    May 9, 2023

    Read time: 10 min

    Key takeaways
    Overview

    Picture a 1,000-piece jigsaw puzzle of a frightening image with a single piece missing. No matter which piece is missing, the image is still frightening. Now picture the same jigsaw puzzle with 400 pieces missing. The image may appear to be terrifying if you squint at the pieces that are there, but it’s possible that if the gaps were filled in, the image would not be troubling. Enter Internal Revenue Service (IRS) Private Letter Ruling (PLR) 202306009, the jigsaw puzzle with 400 pieces missing. In this case the missing pieces are the relevant facts. The IRS is required to redact identifying information from letter rulings before publication but can sometimes be overzealous with the Sharpie, making the published ruling difficult to analyze. Such is the case with PLR 202306009. But because this ruling deals with an important issue for tax-exempt organizations—how to structure business arrangements with founders and other “insiders”—it is worth the effort to try to piece it together.

    In depth

    Background

    In PLR 202306009, the IRS revoked the Section 501(c)(3) status of a nonprofit organization (Charity) dedicated to providing foster care services, including child placement and family support services. The stated basis for the revocation was that Charity’s earnings inured to the benefit of Charity’s founder and his spouse. With the hope that the reader is sitting down while reading this part of the summary, inurement was found despite the following facts:

    • Compensation was never alleged to be excessive (in fact, there are facts suggesting that at least the initial compensation was below fair market value).
    • The agreement at issue appears to have been reviewed and approved by an independent board that relied on comparable arrangements prior to giving its approval.
    • The compensation arrangement did not create an equity-like incentive.

    Given the severity of the punishment (i.e., the IRS found that the result of the arrangement was so egregious as to warrant revocation of tax-exempt status as opposed to the imposition of intermediate sanctions penalties), it is important to clearly identify the pieces of the puzzle that we have and the pieces of the puzzle that are missing.

    The Pieces We Have

    • Charity was formed for the purpose of providing foster care services, including related counseling and training. The IRS stated that this purpose was a qualifying charitable purpose.
    • After several years of Charity’s operation, the executive director and founder of Charity and his wife formed a for-profit management company (ManageCo) to provide management services to Charity and potentially other organizations.
    • A management agreement was drafted and submitted to Charity’s board of directors for approval. Charity’s board looked at comparable arrangements and market research prior to approving the agreement with ManageCo, but there was no competitive bidding process.
    • Under the management agreement, ManageCo provided fairly routine management services, including the provision of an executive director to Charity (who presumably was the founder and previous executive director). Other services included administrative support, financial reporting and budgeting, coordination with auditors, information technology support, human resources support, program development and strategic planning, and database management to meet legal requirements for foster care providers across multiple states.
    • There appear to have been frequent operational meetings between staff of Charity and ManageCo.
    • ManageCo retained the right to own any copyrights and other intellectual property that was created during the term of the agreement.
    • The length of the management agreement term is redacted, but there is no discussion of it being excessive in length. The agreement automatically renewed, with either party having the right to terminate the agreement prior to renewal.
    • The compensation was based on a percentage of gross revenues and was initially set at what appears to be a below-market level because of Charity’s limited financial ability to pay. The management fee was subsequently increased at least twice as Charity’s budget grew, each time by written agreement of the parties and based on analysis of market conditions.
    • There was no factual finding that the compensation under the management services agreement was unreasonable or that the term of the agreement was excessive.
    • Charity’s board was tasked with annual assessment and evaluation of ManageCo’s performance and achievement of stated objectives.
    • ManageCo had the right to provide similar services to other entities, but Charity was “the main client” of ManageCo based on IRS review of ManageCo’s tax returns. The “vast majority” of management fees that Charity paid to ManageCo were in turn transferred to the founder and his wife through salary and shareholder distributions from ManageCo.

    The Pieces We’re Missing

    • What percentage of Charity’s expenses did the management fee represent? If an extremely large percentage of a nonprofit’s expenditures are paid to an entity owned by insiders (or even unaffiliated for-profit entities), that fact can be evidence of more than incidental private benefit and can threaten tax exemption. This was the case in Church by Mail, a case that the IRS relied on heavily in this ruling, but which had more egregious facts. However, the mere percentage in and of itself is not determinative and is simply one fact to be considered in the overall analysis. In the United Cancer Council case, for example, the percentage of contributions retained by the for-profit fundraiser was certainly eyebrow raising but, according to the courts, was merely a percentage that needed to be reviewed in the overall facts and circumstances.
    • How credible were the comparables and market research that Charity’s board used in its review? Were any other management companies even in existence in the area that could have provided the same services as well or as cheaply as ManageCo did?
    • Did ManageCo provide services to other entities or at least offer its services to other entities? If ManageCo had been formed solely to provide services to Charity, that is a fact that the IRS has used historically to support more than incidental private benefit arguments. However, in the letter ruling, the facts stated that there was an intention for ManageCo to provide services to other entities, and that the management fee was not the only source of income to ManageCo.
    • Were the founder and/or the founder’s spouse on Charity’s board of directors? If they were, did they participate in the review and approval process of the arrangement, or did they recuse themselves? The likely answer is that the board was entirely independent because otherwise the IRS would have noted this adverse fact as a basis for supporting its conclusion.
    • Was the management agreement dated retroactively? In the facts, there is a mention of two agreements and a suggestion that the first agreement was effective on a retroactive basis. In the second agreement, which appears to have replaced the first agreement, there is no discussion of retroactivity. Retroactive effective dates can raise issues but are not per se improper; frequently parties agree to business terms and formal documentation is drafted later with retroactive application clearly spelled out. In the analysis section of the letter ruling, the IRS doesn’t mention the retroactive effective date issue, so presumably it was not problematic or used as a basis for revocation.

    Putting the Pieces Together

    There is no question that a meaningful perception issue is raised whenever a charitable organization enters into business arrangements with insiders or their businesses. Such arrangements, however, are not prohibited for Section 501(c)(3) public charities and are not uncommon. It is also not uncommon for nonprofits to outsource various management and administrative services. Unfortunately, given the limited number of facts provided to us in PLR 202306009 due to redactions, it is impossible to determine whether the IRS actions in this specific situation were correct or overreaching.

    What we can see in the puzzle is several very troubling statements made by the IRS that are either incorrect or overstated. For example, twice in the ruling the IRS states that the arrangement with ManageCo was not an arm’s length arrangement simply because Charity did not put the arrangement out for competitive bidding. While relying on comparables is certainly part of an arm’s length analysis, whether an arrangement is put out for competitive bidding is not. (See generally, the regulations under Section 482 of the Internal Revenue Code.) In the ruling there was no question that ManageCo had excellent credentials to provide the relevant services; the only issue was whether there were better and/or cheaper services available.

    The IRS also found that the management agreement gave “substantial control” over Charity to ManageCo, and therefore indirectly to the founder and his wife as insiders. This conclusion is troubling because the specific provisions cited by the IRS in support of such finding seem fairly routine for management services agreements. In particular, the IRS found it suspect that the financial interests of Charity and ManageCo were aligned under the management agreement: because ManageCo would provide expertise in strategic planning and program development, this would have the effect of increasing Charity’s revenues, which would in turn increase the fee paid to ManageCo (recall that the IRS did not find that the fee ever exceeded fair market value).

    Finally, it is concerning that the IRS looked beyond the charitable organization itself to find grounds for revocation. The IRS cited ManageCo’s apparent lack of other meaningful customer relationships, and its decisions regarding salary payments and shareholder distributions, in support of the conclusion that Charity’s tax exemption should be revoked. Assuming that Charity’s board was in fact independent at the time the management agreement was approved, it is unclear how the board would be in a position to evaluate the management company’s business model and financial plans to analyze whether private inurement might occur.

    Takeaways from PLR 202306009

    Unless the case makes its way to court, we’ll never know whether the revocation in PLR 202306009 was appropriate under the specific facts and circumstances. However, much can still be learned from the pieces that we have. When considering any arrangement between a Section 501(c)(3) organization and an insider, or a business entity owned by an insider:

    • Recognize the apparent importance of a competitive bidding process to the IRS. The ruling reflects a new focus on this procedural step in a nonprofit board’s analysis of a proposed business arrangement, particularly where insiders are involved.
    • Clearly document the comparables that the board used in making its decision and the basis for approving the arrangement.
    • Ensure a robust conflict of interest policy is in place and that its procedures are precisely followed.
    • Include express provisions in management agreements to confirm that ultimate authority remains with the nonprofit’s board.

    Even if all of these steps are taken, business arrangements between a charitable organization and its insiders are subject to a heightened degree of scrutiny. Nonprofit boards should exercise additional care when considering such arrangements, especially given the lack of clarity provided in this recent ruling.

    Authors

    Robert C. Louthian , III

    Counsel

    Washington, DC

    More insights

  • CMA Blocks Microsoft’s Acquisition of Activision Blizzard; ‘Game Over’ for Behavioral Remedies?

    CMA Blocks Microsoft’s Acquisition of Activision Blizzard; ‘Game Over’ for Behavioral Remedies?

    ARTICLE / CLIENT ALERT

    CMA Blocks Microsoft’s Acquisition of Activision Blizzard; ‘Game Over’ for Behavioral Remedies?

    May 8, 2023

    Read time: 10 min

    Key takeaways
    Overview

    On April 26, 2023, the Competition and Markets Authority (CMA) blocked what would otherwise have been the largest deal in the gaming industry to date. The decision highlights several important trends, such as:

    • In dynamic markets, regulators are focusing in on whether a deal harms or could harm future competition (i.e., innovation based on predications raising significant uncertainties). The CMA speculated that the deal would “alter the future of the fast-growing cloud gaming market” and preferred to maintain the status quo with the block.
    • Regulators are focusing more and more on non-horizontal relationships and supply chain issues, particularly if one party is vertically integrated. Whereas in the past, concerns could often be remedied via behavioral commitments, more and more deals with a vertical component are now being outright prohibited.
    • While the industry expects the European Commission (Commission) to accept the behavioral remedy (license package) offered by Microsoft, this case shows once again that the CMA and the Commission can reach different conclusions when reviewing the same transaction.
    In depth

    BACKGROUND

    Gaming is the United Kingdom’s largest entertainment sector in terms of revenue. In early 2022, Microsoft announced its plans to acquire Activision Blizzard (Activision) for nearly $69 billion, making it the biggest deal ever in the gaming industry.

    While Microsoft is best known for its Windows operating system (OS), it is also active in gaming through its Xbox console and 24 game development studios, several of which it acquired in recent years. Through the Xbox console, Microsoft competes most closely with Sony’s PlayStation and to a lesser degree with Nintendo’s Switch.

    Importantly, with Xbox Cloud Gaming and Azure, Microsoft also has a global cloud computing infrastructure.

    Cloud gaming is a relatively new alternative to consoles and PCs. Whereas the more traditional methods of gaming require users to download and run games locally on their devices, cloud gaming services dispense with the need for powerful (and often expensive) hardware. These games run on remote servers and can be streamed directly to any device with a stable high-speed internet connection and a display (e.g., a smart TV).

    Activision, on the other hand, has no cloud gaming infrastructure. Rather, it is a leading video games publisher whose most popular titles include Call of Duty, World of Warcraft and Candy Crush. These games run on PCs and consoles, as well as on mobile devices.

    Therefore, while there are actual horizontal overlaps between Activision and Microsoft (with both developing and selling games), the CMA investigation focused on the vertical effects of the proposed transaction in console gaming and in cloud gaming services.

    THE CMA’S DECISION

    Console Gaming

    The first theory of harm considered a scenario where Microsoft would make the game Call of Duty either exclusive to Xbox or only available to its rival PlayStation on worse terms. The concerns that the CMA expressed in its provisional findings have in the meantime been dismissed after revisiting the evidence submitted by Microsoft and Activision. The CMA therefore held, in unanticipated addendum provisional findings (nearly two months after the provisional findings were issued), that Microsoft had no incentive to implement a (partial) foreclosure strategy by either offering PlayStation games, in particular Call of Duty, with lesser quality, at a higher price or not at all (i.e., making Activision’s games exclusive to Microsoft).

    As a result, the CMA concluded that the deal would not result in a substantial lessening of competition (SLC) in console gaming services in the United Kingdom.

    Cloud Gaming

    The second theory of harm considered the ability, incentive and potential impact of Microsoft harming its cloud gaming rivals by making Activision games exclusive to its own cloud gaming offering.

    Against the backdrop of robust growth projections due to lower hardware requirements and thereby lower costs, the CMA found cloud gaming to be “transformative” and an “important disruptive force” in the gaming industry, with the potential to replace expensive consoles and gaming PCs altogether for at least some users.

    Microsoft was deemed to hold a strong position not only in the gaming industry more generally (with its “gaming ecosystem,” including the Xbox console, its Game Pass and development studios, as well as the Windows OS for which the majority of PC games are designed), but also in cloud gaming services more specifically (with 60% to 70% market share). The CMA inferred from this that Microsoft could stream games via Xbox Cloud Gaming and Azure from Windows servers without having to pay its Windows licensing fee or adapt games designed for Windows to an alternative OS—and without having to pay a third-party cloud platform fee. Microsoft would therefore have the ability to make games exclusive to its cloud gaming offering and thereby slow the development of the fast-paced cloud gaming market.

    The CMA also found that Microsoft would have an incentive to make Activision’s games, which were deemed to be important for the growing cloud gaming market, exclusive to Xbox Cloud Gaming and Azure. The CMA explained that the cloud gaming market was characterized by elements of direct and/or indirect network effects and that Microsoft could try to gain market power by offering exclusive games on its cloud gaming service. Importantly, the CMA considered that without the deal, Activision would make its games available to all cloud gaming service providers on its own terms.

    The fact that Microsoft had signed agreements with cloud gaming providers NVIDIA, Boosteroid, Ubitus and Nware (the latter post-prohibition) to make games available on their platforms could not resolve the CMA’s concerns regarding the effects of the merger. The CMA explicitly relied on paragraph 7.15 of its Merger Assessment Guidelines and criticized that the agreements applied only to a few providers and that there was “material uncertainty” around their scope, terms and enforceability. In the CMA’s view, the market is characterized by few emerging rivals (none of which are as well-positioned as Microsoft) and significant barriers to entry and expansion. The CMA found that, absent the merger, Activision’s games were likely to become available on and would be a particularly important input to cloud gaming services and any alternatives were likely not sufficient enough to offset the loss incurred to cloud gaming rivals by the foreclosure of Activision content.

    For similar reasons, the CMA did not accept the behavioral remedies proposed by Microsoft to allay the concerns. Microsoft committed to licensing Activision games royalty-free to certain cloud gaming providers for a period of 10 years. Moreover, Microsoft would have given any consumer who acquired an Activision game from it online the right to stream that game in the cloud gaming services that were covered by the remedy. Importantly, Microsoft also offered to appoint a monitoring trustee to monitor and ensure compliance with the remedy, as well as a fast-track dispute resolution mechanism.

    The CMA saw two significant limitations with the proposed remedy. First, it criticized that gamers would have to purchase a game first in order to stream it on certain cloud gaming services and that the latter would thus be precluded from accessing Activision’s games through other strategies, such as multigame subscription services. Second, the CMA pointed out that the remedy did not include PC OSs other than Windows. It argued that since cloud gaming services wishing to stream Activision’s games would have to be compatible with the Windows OS version of those games, non-Windows-based cloud gaming services would be put at a disadvantage. The CMA also found the duration of 10 years to be insufficient and expressed doubts as to the feasibility of monitoring and enforcing the remedy.

    For the above-mentioned reasons, the CMA expected the merger to result in an SLC in cloud gaming services in the United Kingdom because of vertical effects in the form of input foreclosure, which would ultimately harm current and future gamers.

    COMMENTARY

    This decision underscores the CMA’s position—since Brexit—as a global antitrust authority reviewing the largest deals alongside the Commission and US authorities.

    Microsoft has already said that it will appeal the CMA’s decision before the Commission Appeals Tribunal (CAT). The appeal itself will not focus on the substance (i.e., Microsoft will apply for judicial review of the CMA’s decision). If Microsoft is successful in arguing that the CMA acted illegally, irrationally or improperly, the CAT could require the CMA to reassess its approach in concluding on the theory of harm concerning cloud gaming services.

    Several countries have unconditionally cleared the deal, including Japan, South Africa and—only one day after the CMA’s prohibition—Ukraine. Alongside the appeal before the CAT, Microsoft still awaits regulatory approval in other jurisdictions, most notably the European Union (where the Commission has until May 22, 2023, to decide on the remedies) and the United States (where a private plaintiffs’ challenge is to be heard on May 12, 2023, and an administrative trial at the Federal Trade Commission’s internal court is set to start August 2, 2023). If the deal does not receive clearance from all authorities by July 18, 2023, Microsoft will potentially have to pay a break fee of $3 billion to Activision, unless the parties agree to extend the long stop date in the meantime.

    Although the CMA has blocked the deal on the grounds of what looks like a well-established foreclosure theory of harm (cf. ICE/Trayport), its decision is also the expression of more novel and overall, rather vague concerns over the strengthening of a digital ecosystem. More importantly, however, the case reveals a worrisome stance on behavioral remedies, which have traditionally played an important role in removing vertical concerns.

    In its press release, the CMA voiced its general skepticism towards behavioral remedies, which in its words would necessitate an “ongoing regulation of the sector, replacing market forces in a growing and dynamic market with mandated regulatory obligations ultimately overseen, and enforced by, the CMA – in this case at a global level.” The CMA has not accepted any behavioral remedies in the past three years during in-depth investigations. It famously rejected behavioral remedies in its review of the acquisitions of Farelogix by Sabre and Giphy by Meta (formerly Facebook) and instead prohibited these deals. By blocking Microsoft’s proposed takeover of Activision, the CMA reinforces this trend.

    The Commission thus far seems to have taken a different approach. In its Google/Fitbit clearance, the Commission demonstrated its willingness to accept more complex behavioral remedies, including the possibility of an extension of the initial duration and the appointment of a monitoring trustee. In a similar vein, it has accepted behavioral access remedies to remove its concerns over vertical input foreclosure in Meta/Kustomer, whereas the CMA cleared that same deal unconditionally. It remains to be seen whether the two agencies’ approaches will continue to diverge in the future.

    Authors

    Stéphane Dionnet

    Partner

    Brussels

    Max Küttner

    Associate

    Düsseldorf

    More insights